Key words：infection, erythropoietin（EPO), renal anemia 〈Abstract〉 Patients under hemodialysis treatment（HD patient）have an acquired immunodeficiency and are associated with susceptibility to infection and high mortality, although the precise mechanisms underlying the susceptibility of HD patients to infection remain unknown. Our recent studies support the concept that E-CR1 plays a role in susceptibility to infection in HD patients and we discuss the hypothesis in this review. E-CR1 is detected in erythrocytes and plays a role in host defenses as both a complement receptor and a complement suppressor. ／ Immune complex（IC）reacts with complement in the blood, binds to E-CR1, and is transported to the liver and／ or spleen where IC removal and degradation occurs. The production of erythropoietin（EPO）is suppressed in the HD patient, which causes anemia and decreases E-CR1. Recombinant EPO（rEPO）has been given to HD patients with anemia as a routine treatment that increases complement suppressors DAF and CD59. In contrast, the efficacy of rEPO treatment to correct low E-CR1 varies among patients. Host defenses might be compromised in 大井 洋之 望星会鶴見西口病院内科 〒 230
HD patients whose E-CR1 expression remains low after rEPO treatment. E-CR1 expression is genetically regulated by two types of CRI allele（H and L), and E-CR1 expression in the HH type is higher than that in the LL type. In HD patients with anemia, decreased E-CR1 expression was demonstrated in both the HH and LL types. Patients with low E-CR1 develop severe complications with infection including arteriovenous fistula infection and HCV infection being the most frequent complication. In 95 randomly selected HD patients, the percent survival at 5 years was significantly lower for patients with low E-CR1, compared to that of patients with high E-CR1. These studies suggest that E-CR1 plays an important role in host defense in HD patients. Insight into the mechanisms underlying the susceptibility of HD patients to infection will provide a scientific basis for identifying novel treatments for these patients. 図 6 95 patients divided into three groups by E-CR1 levels and their percent survival rates （after 5 years）were studied. The survival rate of the low E-CR1 groups was significantly lower than the high E-CR1 groups （p＜0.01). Data from reference 51 with permission. from S Karger AG Basel.
図 5 Percentage of HCV-positive cases in low （＜20), middle(C20, B30） and high （＜30） E-CR1 groups. HCV-positive cases in the low E-CR1 groups were significantly higher than in the high E-CR1 groups（p＜0.05). Data from reference 51 with permission. from S Karger AG Basel. 
